社区

$Novavax(NVAX)$ An excerpt from a Tipranks article ."Despite the recent run and the company’s vaccine delivering “best-in-class safety, immunogenicity and efficacy data, including against variants of concerns and in booster setting,” relative to peers Moderna and Pfizer, NVAX shares have been highly volatile this year due to regulatory and manufacturing concerns. However, these could soon be put to rest. The company’s partnership with global vaccine manufacturing leader Serum Research Institute of India (SRII), appears to be bearing fruit based on the “robust” CMC data recently generated. This should also help the company with the U.S. EUA filing which should be completed before the end of the year."